Literature DB >> 29895963

AAN unveils new guidelines for MS disease-modifying therapy.

Stefan Bittner1, Frauke Zipp2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29895963     DOI: 10.1038/s41582-018-0026-7

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  2 in total

Review 1.  [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors:  Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal:  Nervenarzt       Date:  2021-07-23       Impact factor: 1.214

Review 2.  The potential of serum neurofilament as biomarker for multiple sclerosis.

Authors:  Stefan Bittner; Jiwon Oh; Eva Kubala Havrdová; Mar Tintoré; Frauke Zipp
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.